Other Track AgendasCancer & Stem Cells | Cell Based Assays | Cell Culture | Circulating Tumor Cells | Flow Cytometry |
Tuesday, 22 January 2013 |
Current Trends in Cellular Therapy Cancer |
| | 09:00 |  | Keynote Presentation From Ballot Box to Bedside – Advancing Stem Cell Therapies, The California Institute for Regenerative Medicine Experience
Ellen Feigal, Senior Vice President, The California Institute for Regenerative Medicine, United States of America
Advancing science into therapies for patients is a complex and expensive path to travel, and the uncertainty of success, particularly for innovative technologies, makes the funding of the translational steps towards and into the clinic, particularly challenging. This keynote will address the role the California Institute for Regenerative Medicine is playing in advancing stem cell science into the clinic, providing information on the scope of programs, initiatives, funding opportunities to help investigators from academia and companies make progress in their research. |
| 10:00 | Noninvasive Techniques for Monitoring Cell Trafficking and Enhanced Homing as part of Cellular Therapy
Joseph Frank, Senior Investigator, National Institutes of Health, United States of America
This presentation will discuss the current available translatable technologies for monitoring the migration of cells in the clinic and what are the pros and cons for using these approaches in tracking cell distribution and fate. In addition, a noninvasive method to enhance homing of stem cells to target tissues will be presented. | 10:30 | Coffee Break and Networking in the Exhibition Hall | 11:15 | Development of New Agents to Treat the Stem Cell Component of Human Prostate Cancers based on Gene Expression Profiling
Norman Maitland, Director, University of York, United Kingdom
Data on experimental approaches for the development of stem cell therapies to treat prostate cancer will be presented. Since stem cells are exquisitely programmed to resist destruction, new pre-clinical assays and agents are required. | 11:45 | Expression of Oncogenic Ras in Lgr5-positive Stem Cells Elicits Tumour Formation
Silvana Libertini, PostDoc, The Beatson Institute for Cancer Research, United Kingdom
A Brief introduction on cancer stem cells, followed by data supporting the possible role of Lgr5+ve cells as cell of origin for skin squamous cell carcinomas and other tumours. | 12:15 | Lunch Break and Networking in Exhibition Hall | 13:30 | Poster Viewing Session | |
Commercialisation of Cellular Therapeutics |
| | 14:15 | Cancelled - Due to Family Illness
Robert Wieder, Professor of Medicine, University of Medicine & Dentistry of New Jersey, United States of America
| 14:45 | Market Trends in the use of Stem Cells for Cancer Therapeutics: From BMTs to Cord Blood
Enal Razvi, Managing Director, Select Biosciences Inc, United States of America
Select Biosciences industry coverage of the stem cells field covers many market segments. In this presentation, we focus upon the use of various classes of stem cells for hematological and solid tumor therapies. Presented here are the use of bone marrow, peripheral blood, and cord blood and the associated market trends. Also, we present the current research efforts in the hematological cancer space plus an analysis of the clinical trials pipeline. Taken together, this presentation will provide a market assessment of the utility of stem cells in cancer therapeutics. | 15:15 | Coffee Break and Networking in the Exhibition Hall | 16:00 |  | Keynote Presentation Autologous Cancer Immunotherapy in Melanoma: Cancer Stem Cells, the Case for Patient-Specific Antigen Sources
Hans Keirstead, Professor of Anatomy and Neurobiology, University of California, Irvine, United States of America
A patient’s own tumor represents an ideal source of antigens to stimulate an immune response in an immunotherapeutic approach. Recent developments in specific media formulations have enabled us to improve upon propagation speed and efficiency, making automation and scalability technically feasible. |
| 17:00 | End of Day One |
Wednesday, 23 January 2013 |
Deployment of Stem Cells for Cancer |
| | 09:00 |  | Keynote Presentation Neural Stem Cell Mediated Cancer Therapy: From Bench to Phase I Brain Tumor Trial
Karen Aboody, Associate Professor, City of Hope, United States of America
|
| 10:00 | Cancer Stem-Like Cells from Colon and Lung Tumors Provide Tools for Drug Discovery and Development
Jennie Mather, Senior Vice President, MacroGenics Inc, United States of America
We have created a series of unique cancer stem cell lines that self renew, reconstitute patient-like tumors from a single cloned cell, and metastasize from xenografts. These lines are used as drug discovery and screening tools. | 10:30 | Coffee Break and Networking in the Exhibition Hall | 11:15 | The Role of Biorepositories in the Advancement of Cellular Therapy Research
Rosario Isasi, Research Associate, McGill University, Canada
This presentation will provide an overview of how biorepositories are contributing to the advancement of cellular therapy and research, with particular focus on efforts directed at the harmonization of ethical, governance and regulatory requirements. Finally, best practices for cell biorepositories as developed by the International Stem Cell Banking Initiative (ISCBI) will be highlighted. | |
Legal and Logistical Challenges in Cellular Therapeutics |
| | 11:45 | The Legal Gateways to the European Market for (Stem) Cell Based Therapies
Timo Faltus, Research Associate, Martin-Luther-University, Germany
The presentation illustrates the legal gateways to the European market for (stem-) cell based products from (basic) research to market approval, reimbursement and patent strategies. | 12:15 | Lunch Break and Networking in Exhibition Hall | 13:30 | Poster Viewing Session | 14:15 | Production of Hematopoietic Cells From ES and IPS Cells
Eric Bouhassira, Professor/Principal Investigator, Albert Einstein College of Medicine, United States of America
| 14:45 | The Future of Stem Cell Banking
Brian Freed, Professor, University of Colorado School of Medicine, United States of America
Umbilical cord blood is now an FDA-licensed biological drug, which has ramifications for the future of all hematopoietic and mesenchymal stem cell products. The international Cellular Therapy Alliance is now promoting the use of cellular therapy products worldwide in an effort to standardize procedures and reduce regulatory burdens. | 15:15 | Close of Conference |
|
Add to Calendar ▼2013-01-22 00:00:002013-01-23 00:00:00Europe/LondonCancer and Stem CellsSELECTBIOenquiries@selectbiosciences.com
